Navigation Links
Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
Date:9/10/2007

ements

Pharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding our business that are not historical facts are "forward-looking statements" that involve risks and uncertainties including without limitation, the risk that there will be a delay in the presentation of safety, tolerability, pharmacokinetic and food effect data from the R7128 Phase 1 single ascending dose study, the risk that there will be a delay in the release of R7128 safety, tolerability, pharmacokinetic and antiviral efficacy data from the R7128 Phase 1 multiple ascending dose study, the risk that the R7128 data from the Phase 1 R7128 single ascending dose study is not accurate or representative, the risk that the preliminary data from the R7128 Phase 1 multiple ascending dose study is not accurate or representative, the risk that our collaboration with Roche will not continue or will not be successful, the risk that the on-going or anticipated clinical trials for any one or more of our product candidates will not be successful and the risk that any one or more of our product candidates will not be successfully developed and commercialized. For a discussion of these risks and uncertainties, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section of our Quarterly Report on Form 10-Q for the quarter ended June 30, 2007 filed with the Securities and Exchange Commission entitled "Risk Factors" and discussions of potential risks and uncertainties in our subsequent filings with the Securities and Exchange Commission.


'/>"/>
SOURCE Pharmasset, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Pharmasset Presents Clevudine and Racivir Data at the International HIV Drug Resistance Workshop
2. Pharmasset Announces Clevudine and Hepatitis C Presentations at EASL
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
5. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
6. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
7. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
8. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
9. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
10. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
11. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2008)...Dec. 1 Older adults who...flow and a greater number of small blood vessels i... at the annual meeting of the Radiological Society...onducted at the University of North Carolina ( U...scans of older adults who exercise to brain scans ...
(Date:11/28/2008)..., November 28 German biotech compa...pecialized HIV monitoring and,AIDS patient follow...ies. In,the year 2008, 2.5 million patient tests ... highly affordable "CyFlow" system, supporting alr...IDS. Due to introduction of the,Partec innovation...
(Date:11/27/2008)...ajority of acute lymphoblastic leukemia relapse ca...of diagnosis , , MEMPHIS, Tenn., Nov. 27 /P...ildren,s Research Hospital have identified distinc...en with acute lymphoblastic leukemia (ALL) that ca...ning treatments for ALL relapse in children and, u...
(Date:11/26/2008)... density, automation and intelligent clinical appl... an all new level , , CHICAGO, Ill., Nov. 2... ( www.siemens.com/healthcare ) highlights the AC...VS)(1), the world,s first multi-use, automated vo...fic Assembly and Annual Meeting of the Radiologica...
Breaking Medicine Technology:Exercise Helps Prevent Age-Related Brain Changes in Older Adults 2Exercise Helps Prevent Age-Related Brain Changes in Older Adults 3German Innovation for HIV/AIDS Diagnostics has Been Used 2.5 Million Times in 2008 2St. Jude Identifies Genomic Causes of a Certain Type of Leukemia Relapse 2St. Jude Identifies Genomic Causes of a Certain Type of Leukemia Relapse 3Siemens Introduces New Standard of Care for Breast Ultrasound 2Siemens Introduces New Standard of Care for Breast Ultrasound 3Siemens Introduces New Standard of Care for Breast Ultrasound 4Siemens Introduces New Standard of Care for Breast Ultrasound 5AspenBio Pharma Announces 2418 Million Private Placement of Common Stock 2354 1AspenBio Pharma Announces 2418 Million Private Placement of Common Stock 2354 2AspenBio Pharma Announces 2418 Million Private Placement of Common Stock 2354 3Insect gut detects unhealthy meal 1702 1Insect gut detects unhealthy meal 1702 2QUITPLAN 28R 29 Services Can Help Minnesotans Kick Tobacco Habit for New Year 8675 1QUITPLAN 28R 29 Services Can Help Minnesotans Kick Tobacco Habit for New Year 8675 2Settlement Reached Between Dilon Technologies and Naviscan on Patent Rights 8671 1
...A, Australia--(BUSINESS WIRE)--Mar 20, 2007 - Aust... announced highly,successful results from its Phas... novel nucleoside reverse transcriptase inhibitor,...fection in,patients with drug-resistant HIV., The ...in,reducing the viral load of patients with drug-r...
...oretic Drug Delivery System, dermal patch and a di...nephrine (IDDS), SEATTLE, March 20, 2007 /PRNews...eattle, WA, a transdermal drug delivery company,...nologies, Inc.,("TTI"), Tokyo, Japan announced t...which administers lidocaine and epinephrine,thro...
Other Medicine Technology:Avexa Reports Positive Phase IIb Result 2Avexa Reports Positive Phase IIb Result 3Avexa Reports Positive Phase IIb Result 4Dharma Therapeutics Shows IDDS Is Effective in Reducing Pain,Associated With Insertion of an Intravenous Catheter in Their Phase,2 Clinical Trial 2Dharma Therapeutics Shows IDDS Is Effective in Reducing Pain,Associated With Insertion of an Intravenous Catheter in Their Phase,2 Clinical Trial 3
(Date:12/1/2008)... Dec. 1 ETHICON, Inc., a Johnson ... completed the divestiture of its Professional Wou...l terms of the transaction are not being disclosed...ne Equity Partners has acquired the Professional W...dvanced wound care brands as PROMOGRAN Matrix Woun...
(Date:12/1/2008)...1 Democratic National C...lowing statement commemorating World AIDS Day on i....newscom.com/cgi-bin/prnh/20080519/DNCLOGO ) , ...DS Day, and while we have made strides, much work ...th a national and global strategy. We must focus ...
(Date:12/1/2008)...., Dec. 1 MassMutual Retirement Se...upport its increasing nonprofit business. Nonprofi...to last year. , , Dan Darby joined MassMut...or the Western region. He reports to M. Palmer Whi..., for MassMutual,s Retirement Services Division, w...
(Date:12/1/2008)..., supplements can also trigger acute organ failure...ay News) -- Antibiotics are the single largest cla...liver injury (DILI), researchers say. , The con...cute liver failure in the United States and is the...re. , DILI is caused by a wide range of prescri...
Breaking Medicine News(10 mins):Health News:ETHICON Completes Divestiture of Professional Wound Care Business to One Equity Partners 2Health News:ETHICON Completes Divestiture of Professional Wound Care Business to One Equity Partners 3Health News:MassMutual Retirement Services Adds Two to Nonprofit Sales Team 2Health News:MassMutual Retirement Services Adds Two to Nonprofit Sales Team 3Health News:Antibiotics Largest Cause of Drug-Induced Liver Damage 2
...study researchers say health professionals and pat...ectively manage the risks associated with over the... headache is one of the most common condition that...ng Over-the-Counter Medications. Some of the other...
...y started with a big bang, bringing hope and aspir...e and nature had ideas of their own. 2001 opened...and man made ones. The first internationally rep... 1st in California when a jet bound for S.F plugge...
...ave now identified a group of genes known as a gen...st cancer patients may be at high risk for having ...gene expressions in 286 tumor samples from 209 lym...were examined. The patients had not received hormo...
...n cause skin cancer – melanoma ,however researcher...ncreased, so has the number of patients surviving ...may have a beneficial influence on some kinds of c...ients who were diagnosed with melanoma in the late...
Other Medicine News:Health News:SARS (Bird Flu) spreading in the Asian continent 2
...int or DIP joint flexioncontractures of any degree... cushions injured fingers so treatment to straight...ster, more successful therapy results. Use during ...aintain gains in motion. Available in small, mediu...
...iation of the finger joints. Lined in gel padding ...ed splints can be worn at night to lessen stress o...owing injury to the PIP joint or DIP joint of the ...gament injuries. Each FingerSled Splint can be use...
FoamWrap Finger Trappers are ideal for use with custom made splints to help restore finger motion. Finger Trappers' non-slip foam lining replaces fingernail hooks and sutures to place the fingers in
One splint does it all.
Medicine Products: